Back to all studies
Not Yet RecruitingNCT06827431

The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression

This study is not yet recruiting. It focuses on depression and currently lists study information in Global.

DepressionDrugFrom 18 Years to 65 Years
Need help deciding?

Ask HopeStage to review this study with me

Loading the security check...
Study ID: NCT06827431. We help you review the study, but cannot decide medical eligibility.
In plain English

Key information made simple

This study is looking at evaluate the efficacy and safety of Ammoxetine hydrochloride enteric-coated tablets in subjects with depression. Participants are followed over time so researchers can learn from clinical and follow-up information. This study may not offer a new treatment, and its main value is helping researchers learn from follow-up information that may improve future care.

What to expect

Your next step

The official record does not clearly spell out the visit format, but it appears to be coordinated directly by the research team. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually matching the main diagnosis and being able to understand the study and consent, while common reasons not to take part include safety concerns that need urgent care first. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateEstimated: February 14, 2025
Recruitment status
Not Yet Recruiting
Estimated enrollment
Not clearly listed
Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Not clearly listed
Locations
Global
Age range
From 18 Years to 65 Years
Official registry ID
NCT06827431
Official source
Official registry link

Want help reviewing this study?

Loading the security check...
Study ID: NCT06827431. We help you review the study, but cannot decide medical eligibility.
Why this study may matter

Why this study may matter

This study may matter because it adds public evidence around depression. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.

In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular visits and structured follow-up.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.

Who might this study be for?

This study may concern people with depression; age range: From 18 Years to 65 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., which appears to be a pharmaceutical company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The registry indicates that this study has not started recruiting yet. You can check the planned start date and available contacts.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in. — Depression Clinical Trial | HopeStage